UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
21.35
+0.83 (4.04%)
Feb 6, 2026, 4:00 PM EST - Market closed

UroGen Pharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
999449463205213398
Market Cap Growth
133.33%-2.93%126.06%-3.94%-46.44%-43.13%
Enterprise Value
1,002318409184105276
Last Close Price
21.3510.6515.008.879.5118.02
PS Ratio
10.524.975.603.184.4433.74
PB Ratio
--51.05-7.10-2.2925.344.13
P/TBV Ratio
----25.344.13
EV/Sales Ratio
10.383.524.952.852.1823.36
Debt / Equity Ratio
-1.13-14.19-1.54-1.120.180.03
Asset Turnover
0.400.390.530.500.400.07
Inventory Turnover
1.461.191.871.671.52-
Quick Ratio
3.475.594.884.714.515.09
Current Ratio
3.996.015.425.395.115.39
Return on Equity (ROE)
-----211.55%-92.88%
Return on Assets (ROA)
-33.96%-25.77%-26.10%-38.69%-47.72%-46.29%
Return on Capital Employed (ROCE)
-92.60%-39.90%-44.60%-70.80%-94.80%-119.50%
Earnings Yield
-16.47%-28.23%-22.08%-53.60%-51.98%-32.27%
FCF Yield
-13.82%-21.60%-16.54%-42.88%-40.17%-26.90%
Buyback Yield / Dilution
-18.43%-48.70%-26.43%-2.05%-2.60%-6.10%
Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q